Serum concentration/dose ratio of levetiracetam before, during and after pregnancy

Seizure : the Journal of the British Epilepsy Association
Andreas Austgulen WestinEylert Brodtkorb

Abstract

To investigate changes in levetiracetam (LEV) serum concentration/dose ratio (C/D-ratio) in relation to pregnancy. Altogether 21 consecutive pregnancies in 20 women with epilepsy receiving LEV during gestation were studied retrospectively. The main target variable was the C/D-ratio before and during pregnancy, and in the post partum period. Secondary target variables were changes in LEV dose, concomitant use of other antiepileptic drugs and seizure frequency. Student's paired t-test and two-sample t-test for independent samples were used to test for statistically significant changes in C/D-ratio means. Mean C/D-ratio in the third trimester was 50% of the mean C/D-ratio at baseline (p<0.001, n=11). Baseline levels were reached within the first weeks after pregnancy. The interindividual variability was pronounced. Serum concentrations of LEV declined significantly in the third trimester of pregnancy and increased rapidly after delivery.

Associated Clinical Trials

References

Nov 26, 2003·Therapeutic Drug Monitoring·Theodor W MayUwe Jürgens
Aug 11, 2004·Clinical Pharmacokinetics·Philip N Patsalos
Apr 29, 2005·Epilepsia·Svein I JohannessenEylert Brodtkorb
Apr 28, 2007·CNS Drug Reviews·Tim De SmedtPaul Boon
Jun 19, 2007·Epilepsia·Lawrence J HirschCarl W Bazil

❮ Previous
Next ❯

Citations

May 24, 2014·Neurobiology of Disease·Emilio PeruccaTorbjörn Tomson
Oct 3, 2008·Neuropsychiatric Disease and Treatment·Bassel Abou-Khalil
Aug 1, 2012·Therapeutic Drug Monitoring·Doreen M Matsui
Jun 18, 2009·Current Opinion in Neurology·Anne Sabers, Torbjörn Tomson
May 29, 2008·Expert Review of Neurotherapeutics·Svein I Johannessen, Cecilie Johannessen Landmark
Jul 1, 2009·Expert Review of Clinical Pharmacology·Armel StockisChristian Otoul
Nov 9, 2011·Advanced Drug Delivery Reviews·Cecilie Johannessen LandmarkTorbjörn Tomson
Sep 15, 2010·Pediatric Neurology·Maria G DahlinInger Ohman
Mar 9, 2010·Thérapie·Eric DaillyUNKNOWN le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique
Apr 19, 2016·Neurologic Clinics·Naymeé J Vélez-Ruiz, Page B Pennell
Apr 14, 2009·Epilepsy & Behavior : E&B·Isabel P López-FrailePedro J Modrego
Feb 25, 2009·Thérapie·Philippe GélissePierre Genton
Jul 1, 2008·Epilepsy & Behavior : E&B·Jan NovyAndrea O Rossetti
Jan 31, 2009·Epilepsia·Andreas Austgulen WestinEylert Brodtkorb
Nov 10, 2011·Pharmacoepidemiology and Drug Safety·Cecilie Johannessen Landmark, Svein I Johannessen
Jun 9, 2014·Seizure : the Journal of the British Epilepsy Association·Arne Reimers
Aug 6, 2013·Epilepsy & Behavior : E&B·T L ReisingerK J Meador
Mar 8, 2014·Reproductive Toxicology·Shahnaz Akhtar ChaudhryGideon Koren
Sep 11, 2009·Epilepsy Research·Inger OhmanTorbjörn Tomson
Dec 26, 2007·Seizure : the Journal of the British Epilepsy Association·Eylert Brodtkorb, Arne Reimers
Jun 5, 2012·Seizure : the Journal of the British Epilepsy Association·I HoeritzauerJ Craig
May 10, 2011·Epilepsy Research·Anne Sabers, Jacob Christensen
Jul 21, 2015·Journal of Neurosurgical Anesthesiology·David TurnbullCharles Reilly
Jul 12, 2014·Thérapie·Alice PanchaudNicolas Widmer
Oct 21, 2016·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Page B Pennell
Nov 2, 2016·PLoS Medicine·Gali ParienteGideon Koren
Aug 20, 2009·The Annals of Pharmacotherapy·Brian LongoJulie A Murphy
Mar 29, 2018·Epilepsia Open·Noni RichardsAlesha Smith
Feb 16, 2019·Journal of Women's Health·Sarah Barnard, Jacqueline French
Oct 15, 2019·Therapeutic Drug Monitoring·Kamisha L Johnson-Davis, Kelly Doyle
Apr 17, 2020·European Journal of Hospital Pharmacy. Science and Practice·Maria Mendoza AguileraRaúl Ferrando Piqueres
Jan 29, 2011·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Kamal M Matar, Najlaa A Marafie
Jun 2, 2012·Expert Review of Neurotherapeutics·Arne Reimers, Eylert Brodtkorb
Jun 14, 2019·Therapeutic Advances in Chronic Disease·Maya BerlinMatitiahu Berkovitch
Dec 12, 2018·Expert Opinion on Pharmacotherapy·Anna Whelehan, Norman Delanty
Sep 2, 2021·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Luisa MariFrancesca Izzi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.